We are monitoring the impact of COVID-19 on Europe Checkpoint Inhibitors Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 2086
Share on
Share on

Europe Checkpoint Inhibitors Market Research Report – Segmented By Type, Application & By Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends, Forecast, Growth | 2019 - 2024

Pulished: February, 2020
ID: 2086
Pages: 145

Europe Checkpoint Inhibitors Market Size & Growth (2019 – 2024):

According to the report, the Europe Checkpoint Inhibitors Market size is valued at USD 2.6 billion in 2019 and is expected to reach USD 8.95 billion by 2024, growing at a CAGR of 28 % during the forecast period 2019-2024.

Checkpoint Inhibitors are drugs used in Immunotherapy to let the immune system attack cancer cells by blocking checkpoint molecules. Checkpoint molecules are produced by the immune system to avoid damage to the normal cells from the immune system’s attack on infected cells. But, Cancer cells use these molecules to escape the immune system. By blocking these checkpoint molecules, Checkpoint inhibitors help the immune system detect and attack cancer cells.

Rising Prevalence of cancer and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the market. However, high expenses involved in R&D activities is one of the major factors restricting the growth of the market.

CTLA-4 Segment holds the highest share accounting for almost 94 % of the overall market. However, this segment is expected to lose some of its markets to the PD-1 inhibitors segment during the forecast period as the majority of new treatments are based on PD-1 inhibitors.

Europe Checkpoint Inhibitors Market has been segmented and sub-segmented into the following categories

  • By Drug: PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others.
  • By Application: Lung cancer, Renal cancer, Blood cancer, Bladder Cancer, Hodgkin lymphoma, Melanoma, Others.
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe

On the basis of region, Europe is the second-largest market globally owing to the high funding available for clinical trials.

Some of the Promising Companies dominating the Europe Checkpoint Inhibitors Market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Type                   

                                5.1.1 Introduction           

                                5.1.2 PD-1 inhibitors       

                                5.1.3 PD-L1 inhibitors     

                                5.1.4 CTLA-4      

                                5.1.5  Chimeric Antigen Receptor T-cell 

                                5.1.6  Others     

                                5.1.7 Y-o-Y Growth Analysis, By Drug Type           

                                5.1.8 Market Attractiveness Analysis, By Drug Type         

                                5.1.9 Market Share Analysis, By Drug Type          

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 Lung cancer            

                                5.2.3 Renal cancer           

                                5.2.4 Blood cancer          

                                5.2.5 Bladder Cancer      

                                5.2.6  Hodgkin lymphoma            

                                5.2.7 Melanoma              

                                5.2.8  Others     

                                5.2.9 Y-o-Y Growth Analysis, By Application         

                                5.2.10  Market Attractiveness Analysis, By Application   

                                5.2.11  Market Share Analysis, By Application     

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Drug Type

                                                6.1.3.3 By Application

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Drug Type

                                                6.1.4.3 By Application

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Drug Type

                                                6.1.5.3 By Application

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Merck & Co., Inc.                     

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Bristol-Myers Squibb                              

                8.3 Roche                           

                8.4 AstraZeneca                               

                8.5 Ono Pharmaceutical Co., Ltd.                              

                8.6  Juno Therapeutics                  

                8.7 Novartis International AG                    

                8.8 Kite Pharma                               

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  2. Europe PD-1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  3. Europe PD-L1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  4. Europe CTLA-4 Market By Region, From 2019-2024 ( USD Billion )
  5. Europe Chimeric Antigen Receptor T-cell Market By Region, From 2019-2024 ( USD Billion )
  6. Europe Others Market By Region, From 2019-2024 ( USD Billion )
  7. Europe Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  8. Europe Lung cancer Market By Region, From 2019-2024 ( USD Billion )
  9. Europe Renal cancer Market By Region, From 2019-2024 ( USD Billion )
  10. Europe Blood cancer Market By Region, From 2019-2024 ( USD Billion )
  11. Europe Bladder Cancer Market By Region, From 2019-2024 ( USD Billion )
  12. Europe Hodgkin lymphoma Market By Region, From 2019-2024 ( USD Billion )
  13. Europe Melanoma Market By Region, From 2019-2024 ( USD Billion )
  14. Europe Others Market By Region, From 2019-2024 ( USD Billion )
  15. U.K. Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  16. U.K. Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  17. Germany Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  18. Germany Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  19. France Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  20. France Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  21. Italy Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  22. Italy Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  23. Spain Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  24. Spain Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample